01—Abstract
Summary
Summary of the 8-K filed January 21, 2026. Cited figures are marked; the original filing is the authoritative source.
On January 21, 2026, BridgeBio Pharma, Inc. closed a private offering under Rule 144A of $632.5 milliona aggregate principal amount of 0.75% Convertible Senior Notes due 2033.
The total includes $82.5 millionb from the Initial Purchasers' exercise in full of their option. Net proceeds are approximately $619.3 million after the Initial Purchasers' discount and estimated offering expenses. BridgeBio intends to use the proceeds to repurchase, settle conversion obligations in respect of, or repay at maturity a portion of its 2.50% Convertible Senior Notes due 2027, and for general corporate purposes.
The filing states that no assurance can be given as to how much of the 2027 Notes will be repurchased or when. The Notes are senior unsecured obligations that pay interest semiannually on February 1 and August 1, beginning August 1, 2026. They are convertible into cash, shares, or a combination at BridgeBio's election, with an initial conversion rate of 9.0435 shares per $1,000c principal amount, equal to an initial conversion price of approximately $110.58 per share.
BridgeBio may not redeem the Notes before February 6, 2030, and its redemption right is conditioned on the stock trading at or above 130% of the conversion price. The Notes rank equally with the 2027, 2029 and 2031 convertible notes, and are effectively junior to secured debt, including obligations under a Funding Agreement dated January 17, 2024, and structurally junior to subsidiary liabilities. Concurrently with the pricing, BridgeBio used approximately $82.5 milliond of cash on hand to repurchase 1,081,825 shares of common stock from certain purchasers of the Notes in privately negotiated transactions at $76.26 per share, the January 15, 2026 closing price on Nasdaq.
The filing notes these repurchases could have affected the market prices of the common stock or the Notes. Shares issuable on conversion are initially capped at 8,293,972 at a maximum conversion rate of 13.1130 shares per $1,000 principal amount, subject to anti-dilution adjustments. The Notes and underlying shares are unregistered securities.
02—Key points
Key Highlights
- Issued $632.5 million of 0.75% Convertible Senior Notes due February 1, 2033, including the full $82.5 million option exercised by the Initial Purchasers.
- Net proceeds of approximately $619.3 million, intended to prefund repurchase, conversion settlement, or repayment at maturity of a portion of the 2.50% Notes due 2027.
- Initial conversion price of approximately $110.58 per share (9.0435 shares per $1,000 principal), with conversion settleable in cash, shares, or a combination at BridgeBio's election.
- Company repurchased 1,081,825 common shares for approximately $82.5 million of cash on hand at $76.26 per share, the January 15, 2026 closing price.
- No optional redemption before February 6, 2030; thereafter redemption requires the stock to trade at or above 130% of the conversion price for 20 of 30 trading days.
- Notes are senior unsecured and rank equally with the 2027, 2029 and 2031 convertible notes, but are effectively junior to secured debt under the January 17, 2024 Funding Agreement and structurally junior to subsidiary liabilities.
- Maximum of 8,293,972 shares may be issued on conversion at the maximum conversion rate of 13.1130 shares per $1,000 principal, subject to anti-dilution adjustments.
03—Questions
Frequently Asked Questions
What is the company using the proceeds from the Notes for?
The filing states BridgeBio intends to use the net proceeds of approximately $619.3 million to repurchase, settle future conversion obligations in respect of, or repay at maturity a portion of its 2.50% Convertible Senior Notes due 2027, on or before their maturity date, and for general corporate purposes, which may include working capital, capital expenditures and/or debt repayment. It states no assurance can be given as to how much of the 2027 Notes will be repurchased, on what terms, or when.
How could the Notes affect existing shareholders?
The Notes have an initial conversion price of approximately $110.58 per share, and up to 8,293,972 shares may be issued on conversion at the maximum conversion rate of 13.1130 shares per $1,000 principal. BridgeBio may settle conversions in cash, shares, or a combination, at its election. The conversion rate is subject to anti-dilution adjustments and an increase for certain corporate events.
When can the Notes be redeemed or converted by holders?
BridgeBio may not redeem the Notes before February 6, 2030. From that date until the 21st scheduled trading day before maturity, it may redeem for cash at 100% of principal plus accrued interest if conditions are met, including a last reported sale price at least 130% of the conversion price for 20 trading days within a 30-day period. Holders may convert before November 1, 2032 only under specified conditions, and at any time from November 1, 2032 until the second scheduled trading day before maturity.
What was the purpose of the concurrent share repurchase?
BridgeBio used approximately $82.5 million of cash on hand to repurchase 1,081,825 shares of its common stock from certain purchasers of the Notes in privately negotiated transactions at $76.26 per share, the January 15, 2026 Nasdaq closing price. These transactions were entered into concurrently with the pricing of the Notes. The filing states the repurchases could have increased or reduced the market price of the common stock or the Notes.
04—Continue